Instil Bio, Inc. (TIL) Stock Price & Analysis
Instil Bio, Inc. (TIL) fell 0.26% to USD 7.58 as of September 8, 2026 at 05:48 UTC, according to Nexqual real-time market data.
TIL last closed at USD 7.58; the session ranged USD 7.58–7.64 on volume of 2,747 shares. Market capitalization is —, with a 52-week range of USD 5.67–28.43 (NCM). Source: Nexqual, September 8, 2026 at 05:48 UTC.
Key Statistics (as of September 8, 2026 at 05:48 UTC)
| Price | USD 7.58 |
|---|---|
| Change | ▼ 0.26% (down) |
| Previous Close | USD 7.58 |
| Open | USD 7.58 |
| Day Range | USD 7.58 – 7.64 |
| 52-Week Range | USD 5.67 – 28.43 |
| Volume | 2,747 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (TIL)
Nexqual's technical model rates TIL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:48 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.8 (neutral) |
| vs SMA50 | Above (USD 7.48) |
| MACD | 0.07 (positive) |
From Instil Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.
- Prior to developing AXN-2510, our development efforts were focused on pursuing the development of cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for the treatment of cancer.
- We believe that our approach, strategy and experience provide us with certain competitive advantages.
Partnerships
- The license and collaboration agreement with ImmuneOnco was terminated in January 2026.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | USD 15.14 | ▼ 2.51% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.97 | ▼ 3.18% |
| FTH | Faeth Therapeutics, Inc. | USD 40.05 | ▲ 2.38% |
| LYEL | Lyell Immunopharma, Inc. | USD 14.37 | ▼ 3.91% |
| ANNX | Annexon, Inc. | USD 4.87 | ▼ 1.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:48 UTC. This page is informational and not investment advice.